Monoclonal Antibodies for Inflammatory Bowel Disease Take Center Stage At Digestive Disease Week
This article was originally published in The Pink Sheet Daily
Executive Summary
Studies of Biogen Idec/Elan's Antegren, Abbott's Humira and Protein Design Labs' HuZAF for Crohn's disease were presented at the meeting. Presentations of non-MAb's included Otsuka's OPC-6535, Alizyme's renzapride and Solvay's cilansetron.
You may also be interested in...
Tysabri's Next Steps Include Rheumatoid Arthritis, Crohn's Indications
Elan/Biogen Idec may price the recently approved Tysabri at a premium to other multiple sclerosis therapies in anticipation of the additional indications. The price announcement could come within a few days.
Tysabri's Next Steps Include Rheumatoid Arthritis, Crohn's Indications
Elan/Biogen Idec may price the recently approved Tysabri at a premium to other multiple sclerosis therapies in anticipation of the additional indications. The price announcement could come within a few days.
Antegren BLA Submission For Multiple Sclerosis Could See Approval By Year-End
Biogen Idec and Elan are requesting priority review for the MS submission. Companies are also seeking accelerated approval; BLA is based on one-year data from ongoing AFFIRM and SENTINEL trials.